* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document
5-HT2C receptor agonist wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Toxicodynamics wikipedia , lookup
NMDA receptor wikipedia , lookup
Drug interaction wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Psychopharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Neuropharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Aprepitant: A new Drug for Chemotherapy Induced Nausea and Vomiting Girish C Dept. of Pharmacology, JIPMER, Pondicherry, INDIA Introduction Nausea and vomiting -- devastating side effects of antineoplastic agents Uncontrolled emesis affect quality of life and impair compliance with treatment About 70- 80% patients experience emesis & 1044% have anticipatory emesis The potential for Chemotherapy induced Nausea and Vomiting (CINV) is influenced by Emetogenic potential of antineoplastic agents Patient related factors Emetogenic Potential of Antineoplastic agents Navari RM. Pathogenesis-based treatment of chemotherapy – induced nausea and vomiting – Two new agents. J Support Oncol 2003;1:89-103 Patient Related Risk Factors Navari RM. Pathogenesis-based treatment of chemotherapy – induced nausea and vomiting – Two new agents. J Support Oncol 2003;1:89-103 Types of CINV Acute CINV: Nausea and vomiting with in the first 24 hrs of chemotherapy Delayed CINV: After 24 hrs lasting up to 5 days Anticipatory CINV: After a negative past experience with chemotherapy Breakthrough CINV: Occurs despite patient being treated with preventive therapy Refractory CINV: Occur during subsequent cycles of chemotherapy when antiemetic prophylaxis has failed in earlier cycles Pathophysiology of CINV Cerebral cortex Cancer chemotherapy Chemoreceptor Trigger Zone (CTZ) (Outside BBB) Dopamine 5 HT, substance P Smell Sight Thought Anticipatory emesis Vomiting Centre (medulla) Ach, 5 HT Histamine & Substance P Chemo & radio therapy Pharynx & GIT 5 HT & Substance P Approaches in the management of CINV Serotonin Substance P Endorphins Dopamine Emetic center Histamine Acetylcholine Dopamine receptor antagonists( Metoclopramide, Phenothiazines, butyrophenones) 1990- First selective 5 -HT3 receptor antagonist introduced (Ondansetron ) Addition of dexamethasone further improved these symptoms ( Acute emesis up to 60-70%) Limitations Ineffectiveness in delayed emesis Not effective in all patients Ineffective once symptoms develop Focus on New Targets… Substance P - belongs to tachykinin family of peptides Neurokinin A &B are other members Present in CNS( neurotransmitter), GIT( transmitter in enteric nervous system & act as local hormone) Implicated in behavior, anxiety, depression, nausea& vomitting Tachykinins act through Neurokinin type 1(NK1) , NK2 & NK3 receptor Substance P is the major ligand for NK1 NK1 receptors are dense in NTS, DMVN and vagal afferent nerve fibers in GIT Blockers of NK1 receptor lessen emesis in experimental studies Aprepitant is first drug of NK1 receptor antagonists Aprepitant Non peptide, selective, Neurokinin type 1 (NK 1) receptors antagonist Block substance P from binding to NK1 receptor Broader spectrum and activity in delayed emesis (In Preclinical studies) Augment the antiemetic activity of 5HT3 receptor antagonists and dexamethasone Inhibit both acute and delayed CINV Chemistry Empirical formula: C23H21F7N4O3 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one Pharmacokinetics Orally active Bioavailability of 60-65%... unaffected by food Tmax -- after 4 hrs of oral dose Volume of distribution -70 L 95% bound to plasma proteins Crosses BBB & placental barrier Metabolism in liver (CYP3A4) Excreted in urine (50%) and in feces(50%) Drug Interactions A substrate, moderate inducer and moderate inhibitor of CYP3A4 Induces CYP2C9 Pimozide, terfenadine, astemizole and cisapride should not be used concurrently with aprepitant Docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, vincristine Interact with warfarin, dexamethasone, methylprednisolone, oral contraceptives Adverse Effects Asthenia(17.8%), hiccups(10.85%), diarrhoea(10.3%), heartburn(9.5%), dizziness, elevation in LFT values Case reports of angioedema, urticaria, StevensJohnson syndrome Indications and Dose ♣ FDA approved on March 2003 for prevention of acute and delayed CINV with single or repeated courses of highly emetogeneic chemotherapy ♣ 125 mg on day 1 (before chemotherapy) and then 80mg on days 2 and 3(after chemotherapy) ♣ Should be given with a 5HT3 antagonist and dexamethsone ♣ Dose of dexamethasone should be reduced by 50% Clinical Trials o Hesketh PJ et al.,Poli-Bigelli S et al., o Multicenter, randomized, double blind placebo controlled study o Chemotherapy naïve patients receiving highly emetogenic chemotherapy including Cisplatin≥ 70mg/m2 Dose Schedule Ondan 32mg iv Apre 20 125mg Dexa mg oral Ondan 32mg iv Apre 80mg Dexa 12 mg oral Days 1 2 3 4 5 6 7 Days 1 2 3 Dexa 8mg b d 4 5 6 7 Dexa 8mg Summary of the main results from the phase III aprepitant trials (Complete response= No emesis and no rescue therapy) Thein H Oo, Hesketh PJ. Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting .Nature Clinical Practice Oncology ,2005; 2 :196-201 National Comprehensive Cancer Network(NCCN) Guidelines High Emetic Risk Chemotherapy- Emesis prevention Moderate Emetic Risk Chemotherapy- Emesis prevention Patient Counseling Dosing schedule should be explained Should not be taken as monotherapy If breakthrough CINV occurs, take lorazepam or prochlorperazine Herbal drug interactions Alternative contraceptive methods for women on oral contraceptives Other NK1 receptor Antagonists… Vafopitant CP-122,721 CJ-11,794 L-758,298 Future Directions • Use with other antiemetic combinations • Use in multiday chemotherapy, in stem- cell transplantation and pediatric patients • Use in other moderately emetogenic settings • Results of trials with other NK1 antagonists Summary Aprepitant – a clear-cut therapeutic advance Good safety profile Effective in Breast cancer patients (cyclophosphamide/anthracycline based chemotherapy) Potential for drug interactions High cost of the drug References: 1. Kris MG. Why Do We Need Another Antiemetic? Just Ask. Journal of Clinical Oncology, 2003; 21:4077-80. 2. Tramèr MR. Treatment of postoperative nausea and vomiting .Better data, improved control have been achieved during recent years. BMJ 2003;327:762–3. 3. Rittenberg CN. A new class of antiemetic agents on the horizon. Clinical journal of Oncol Nursing 2002;6:103-4. 4. Huskey SW, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W,et al.,Brain penetration of aprepitant, a substance p receptor antagonist, in ferrets ,Drug Metabol Dispos 2003 ;31:785–91. 5. Saito R, Takano Y, Kamiya H. Roles of substance P an NK1 receptor in brain stem in the development of emesis. J Pharmacol Sci 2003; 91: 87-94. 6. Navari RM. Pathogenesis-based treatment of chemotherapy – induced nausea and vomiting – Two new agents. J Support Oncol 2003;1:89-103. 7. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002; 3(Suppl 11):18-24. 8. Sanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs for to treat gastrointestinal motility disorders and pain. BJP 2004; 141:1303-1312. Thank You